Cognition Therapeutics, Inc. (CGTX) Income Statement
CGTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCGTX revenue and net income
CGTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CGTX quarterly EPS vs estimates
Cognition Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.07).
CGTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $228,000 | $266,000 | $252,000 | $235,000 | $93,000 | $98,000 | $81,000 |
| Gross profit | −$228,000 | −$266,000 | −$252,000 | −$235,000 | −$93,000 | −$98,000 | −$81,000 |
| Research & development | $37.2M | $41.7M | $37.2M | $30.3M | $18.6M | $12.9M | $14.4M |
| Sales, general & admin | $10.6M | $12.3M | $13.8M | $13.2M | $10.0M | $4.5M | $3.5M |
| Total operating expenses | $47.8M | $54.0M | $50.7M | $43.3M | $28.6M | $17.3M | $4.7M |
| Operating income | −$47.8M | −$54.0M | −$50.7M | −$43.6M | −$28.6M | −$17.4M | −$17.8M |
| Interest expense | $13,000 | $25,000 | $27,000 | $28,000 | $893,000 | $1.8M | $1.0M |
| Income before taxes | −$23.5M | −$34.0M | −$25.8M | −$21.4M | −$11.7M | −$7.8M | −$4.8M |
| Income taxes | — | — | — | −$22.2M | −$1.4M | $2.2M | $2.1M |
| Net income | −$23.5M | −$34.0M | −$25.8M | $757,000 | −$11.7M | −$10.1M | −$7.0M |
| EBITDA | −$23.2M | −$33.7M | −$25.5M | −$21.1M | −$10.7M | −$6.0M | −$3.7M |
| EPS (diluted) | −$0.33 | −$0.89 | −$0.86 | −$0.91 | −$17.27 | −$7.24 | −$7.58 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $250,000 | $0 | $0 | $0 | $372,000 | $0 |
| Cost of revenue | — | $68,000 | $61,000 | $61,000 | $61,000 | $45,000 | $71,000 | $70,000 | $67,000 | $58,000 | $66,000 | $65,000 |
| Gross profit | — | −$68,000 | −$61,000 | −$61,000 | −$61,000 | −$45,000 | −$71,000 | −$70,000 | −$67,000 | −$58,000 | $306,000 | −$65,000 |
| Research & development | $5.1M | $6.1M | $11.1M | $3.8M | $11.5M | $10.8M | $8.2M | $11.4M | $11.6M | $10.6M | $11.6M | $11.7M |
| Sales, general & admin | $2.6M | $2.7M | $2.5M | $2.6M | $2.5M | $3.0M | $2.6M | $3.1M | $3.2M | $3.6M | $3.7M | $3.1M |
| Total operating expenses | $7.7M | $8.7M | $13.7M | $6.3M | $14.0M | $13.8M | $10.7M | $14.5M | $14.7M | $14.0M | $15.2M | $14.7M |
| Operating income | −$7.7M | −$8.8M | −$13.7M | −$6.4M | −$14.0M | −$13.8M | −$10.7M | −$14.5M | −$14.7M | −$14.1M | −$15.2M | −$14.7M |
| Interest expense | $3,000 | $5,000 | $5,000 | $0 | $3,000 | $5,000 | $5,000 | $3,000 | $7,000 | $10,000 | $9,000 | $2,000 |
| Income before taxes | −$3.9M | −$4.6M | −$3.3M | −$4.9M | −$6.7M | −$8.5M | −$7.8M | −$9.9M | −$7.0M | −$9.2M | −$8.1M | −$6.7M |
| Income taxes | — | — | — | — | — | — | — | — | — | $14,724 | $2.3M | $316,000 |
| Net income | −$3.9M | −$4.6M | −$3.3M | −$4.9M | −$6.7M | −$8.5M | −$7.8M | −$9.9M | −$7.0M | −$9.2M | −$8.1M | −$6.7M |
| EBITDA | −$3.9M | −$4.5M | −$3.3M | −$4.9M | −$6.7M | −$8.4M | −$7.8M | −$9.9M | −$7.0M | −$9.1M | −$8.1M | −$6.7M |
| EPS (diluted) | −$0.04 | −$0.05 | −$0.02 | −$0.06 | −$0.11 | −$0.14 | −$0.19 | −$0.25 | −$0.18 | −$0.27 | −$0.27 | −$0.22 |
| Gross margin | — | — | — | — | — | — | −28.4% | — | — | — | 82.3% | — |
| Operating margin | — | — | — | — | — | — | −4,289.2% | — | — | — | −4,083.1% | — |
| Net margin | — | — | — | — | — | — | −3,136.8% | — | — | — | −2,188.4% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CGTX's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CGTX financial results
Cognition Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $23.5 million. Diluted earnings per share came to −$0.33.
See the CGTX stock overview for the latest quote and news, or the CGTX chart for price history and technical indicators.
CGTX income statement FAQ
Does Cognition Therapeutics have revenue?
Cognition Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Cognition Therapeutics profitable?
No. Cognition Therapeutics reported a net loss of $23.5 million in fiscal 2025.
How much does Cognition Therapeutics spend on research and development?
Cognition Therapeutics spent $37.2 million on research and development in fiscal 2025.
What are Cognition Therapeutics's earnings per share?
Cognition Therapeutics earned $-0.33 per diluted share in fiscal 2025, compared with $-0.89 a year earlier.
When will Cognition Therapeutics report its next earnings?
Cognition Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Cognition Therapeutics's fiscal year end?
Cognition Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.